Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Semler to Report Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call on March 10, 2017

SMLR

PR Newswire

PORTLAND, Ore., Feb. 16, 2017 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that provides technology and software solutions to improve the clinical effectiveness of healthcare providers, today announced that it will report fourth quarter and full year 2016 financial results before the open of U.S. financial markets on March 10, 2017. Doug Murphy-Chutorian, M.D., chief executive officer of Semler, will host a conference call at 11 a.m. ET the same day.

The conference call may be accessed by dialing 877-359-9508 for domestic callers and 224-357-2393 for international callers. Please specify to the operator that you would like to join the "Semler Fourth Quarter and Full Year 2016 Financial Results Call, conference ID#: 70178533." The conference call will be archived on Semler's website at www.semlerscientific.com.

About Semler Scientific, Inc.:

Semler Scientific, Inc., is an emerging growth company that provides technology and software solutions to improve the clinical effectiveness of healthcare providers. Its mission is to develop, manufacture and market innovative proprietary products and services that assist its customers in evaluating and treating chronic diseases. Semler Scientific's first patented and U.S. Food and Drug Administration, or FDA, cleared product, introduced commercially in 2011, measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease. In March 2015, Semler Scientific received FDA 510(k) clearance for the next generation version of this product named QuantaFlo™, which was commercially launched in August 2015 to more comprehensively evaluate its customers' patients for risk of heart attacks and strokes. Semler Scientific believes it is positioned to provide valuable information to its insurance company and physician customers, which in turn permit them to better guide patient care. Additional information about Semler Scientific can be found at semlerscientific.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/semler-to-report-fourth-quarter-and-full-year-2016-financial-results-and-host-conference-call-on-march-10-2017-300408327.html

SOURCE Semler Scientific, Inc.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today